Glenmark Pharmaceuticals Ltd, founded in 1977, is a global pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceuticals, focusing on novel chemical (NCEs) and biological entities (NBEs). The company targets oncology, respiratory, and dermatology therapeutic areas and operates 14 manufacturing facilities across the US, India, and Europe. Glenmark has a robust presence in emerging markets via its branded generics business, while its API business serves over 80 countries, including the US and EU.
The company has a history of strategic partnerships and acquisitions, enhancing its global footprint. Recent developments include the launch of innovative products like Ryaltris, a novel nasal spray for allergic rhinitis, and a strategic collaboration for COVID-19 treatment with Nitric Oxide Nasal Spray. Glenmark continues to expand its generics portfolio, with significant operations in the US, and maintains a strong pipeline of drug approvals and launches, positioning itself as an innovation-led global pharmaceutical entity.
